caa a22 4500 38809558X CHVBK 20180307125303.0 cr unu---uuuuu 161130e199907 xx s 000 0 eng 10.1017/S1092852900011998 doi S1092852900011998 pii (NATIONALLICENCE)cambridge-10.1017/S1092852900011998 Goodnick Paul J. Psychopharmacology of Depression in the Next Millennium [Elektronische Daten] [Paul J. Goodnick] Over the last half of the 20th century, there have been a series of psychopharmacologic strategies for treatment of depression. As we approach the next century, new therapies in varying stages of American release are being developed. This review will focus on information available for the following proposed antidepressants: 1) reboxetine, a norepinephrine selective reuptake inhibitor; 2) milnacipran, a combined serotonin/norepinephrine reuptake inhibitor; 3) a new enantiomer of fluoxetine, a selective serotonin reuptake inhibitor; 4) duloxetine, another combined serotonin/norepinephrine reuptake inhibitor; 5) sunepitron, a combined 5-HT1A agonist and α2 antagonist; and, 6) MK-869, a substance P inhibitor. Finally, other possible developing directions will be reviewed, including corticotropin-releasing factor. Copyright © Cambridge University Press 1999 CNS Spectrums Cambridge University Press 4/7(1999-07), 21-35 1092-8529 4:7<21 1999 4 CNS https://doi.org/10.1017/S1092852900011998 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1017/S1092852900011998 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Goodnick Paul J. NATIONALLICENCE 773 0- CNS Spectrums Cambridge University Press 4/7(1999-07), 21-35 1092-8529 4:7<21 1999 4 CNS CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-cambridge